Systemic juvenile idiopathic arthritis in people 8 months and older
Anakinra is recommended as an option for treating Still’s disease with moderate to high disease activity, or continued disease activity after non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. It is only recommended for:
*adult-onset Still’s disease that has responded inadequately to 2 or more conventional disease?modifying antirheumatic drugs (DMARDs)
*systemic juvenile idiopathic arthritis in people 8 months and older with a body weight of 10 kg or more that has not responded to at least 1 conventional DMARD.